New Avon hires Helene F. Rutledge as chief innovation officer
Prior to joining New Avon, Ms. Rutledge was the Vice President of Research and Development for Nature’s Bounty, Inc., where she led Product and Partner Development across NBTY's diverse brands and geographies, including solid dose, liquid, powder, food and cosmetic form products.
As an expert on innovation, Ms. Rutledge is currently an invited member of Henry Chesbrough's OI Forum, and previously served as the Head of Global Open Innovation for GlaxoSmithKline Consumer Healthcare and Senior Vice President of Technology at AeroDesigns.
During her time at AeroDesigns, Ms. Rutledge collaborated with David Edwards, inventor of inhaled insulin, at his incubator Le Laboratoire in Paris.
She also held operations and product development roles with Pfizer, GoSMILE and Warner-Lambert where she led development of innovation award-winning Listerine(R) PocketPaks.
Additionally, she is the founder of the full-service NYC-based consultancy firm Caliper Innovation, which designs, develops and delivers products and innovation solutions.
Earlier in her career, Ms. Rutledge worked at Avon Products, Inc., leading process development for Fragrance, Children's and Bath products. ■
LATEST MOVES FROM New York
- Edward Campanella to join Arrow Financial as SVP, treasurer, and CFO
- Altaba appoints Richard L. Kauffman as director
- Minerals Technologies appoints Carolyn K. Pittman to board
- Time Inc. appoints Katie J. Stanton to board
- Assurant appoints two to board
More inside POST
I'm pregnant. When to tell my boss? Leadership
Freddie Mac Q2 net loss $322 million Earnings
Hedge fund activism weakens the competition Leadership